Canonical: https://neurodiversity.gklijs.tech/i/85e3dbb73627

# Evidence Remains Sparse for Orexin Inhibitors in ADHD and Autism Sleep

Bioengineer.org

17 November 2026 (2026-11-17)

A systematic review found insufficient, diagnosis-specific evidence to support the clinical use of orexin receptor antagonists for sleep disturbances in ADHD and autism spectrum disorder. Despite the mechanistic plausibility of these drugs in targeting wakefulness without inducing sedation, the existing literature lacks rigorous comparative controls necessary to confirm therapeutic efficacy or safety in these populations. Current pharmacological options for sleep problems in ADHD and autism remain limited, with melatonin showing inconsistent effects and no approved orexin inhibitors for neurodevelopmental conditions or pediatric use.

[Read at Bioengineer.org](<https://bioengineer.org/evidence-remains-sparse-for-orexin-inhibitors-in-adhd-and-autism-sleep/>)

All articles from [17 November 2026](</2026/11/17>). Summaries are AI-generated and may contain errors; the linked article is the authority.

## Get this news by email

Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the [subscribe page](</subscribe>).

## More to read

- [Topics](</topics>)
- [Agenda](</agenda>)
- [Subscribe](</subscribe>)
